Black Diamond Therapeutics (BDTX) Other Non Operating Income (2019 - 2026)

Black Diamond Therapeutics (BDTX) has 8 years of Other Non Operating Income data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Other Non Operating Income fell 15.31% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 19.97% YoY) and the FY2025 annual result came in at $5.8 million, down 16.45% from the prior year.
• Other Non Operating Income eased to $1.2 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q3 2024 to a low of -$234000.0 in Q1 2022.
• A 5-year average of $920411.8 and a median of $1.2 million in 2026 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income soared 2062.5% — and 2025, when it sank 36.02%.
• Tracing BDTX's Other Non Operating Income over 5 years: stood at $115000.0 in 2022, then jumped by 876.52% to $1.1 million in 2023, then surged by 53.61% to $1.7 million in 2024, then dropped by 24.06% to $1.3 million in 2025, then declined by 8.4% to $1.2 million in 2026.
• The last three Other Non Operating Income figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.